bottom announc preliminari result
revenu model consensu driven
surg demand pandem midpoint
oper incom rang model
street management maintain guidanc despit
upsid call volatil uncertainti current oper
environ updat model rais
ep estim vs respect
expect come high end net sale
guidanc rang includ number conserv revenu
factor like prgo posit environ owe over-the-counter
defens econom resili privat label portfolio nt
launch gproair voltaren gel off-set us includ
potenti weak wellness/lifestyl categori transient
demand suppli acetaminophen volum
 higher invest outstand binari tax overhang
potenti beyond remain ew-rat see
nt benefactor stock see sentiment
potenti improv post reset
sever
prelim result announc preliminari sale
estim vs con
oper incom non-gaap estim rang
vs estim con
segment level csca sale vs wfse csci
vs wfse rx vs wfse
compani note non-gaap oper incom rang
includ supplement product employe bonus
benefit surg demand like
transient view ceo murray kessler note
continu experi strong growth across busi segment
also benefit dramat surg demand march
relat pandem herculean effort
employe especi product employe around
world abl suppli demand prgo csca
segment suppli acetaminophen volum mani
provid cite tylenol equival better option
treat fever ibuprofen clearli posit
well take advantag phenomenon see demand
surg like transient beyond next coupl month depend
longev pandem management also call rx
sale benefit recent launch gener albuterol sulfat
continu page
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
compani data secur llc estim reuter
guidanc unchang maintain current guidanc net sale growth
ep management call uncertain oper environ due
guidanc view management time provid feb conserv upsid
potenti dr fresh voltaren approv apr guidanc gproair
high end rang ep impli low singl digit ep growth given
higher invest believ greater oper leverag could come well
clariti tax overhang latter part year
estim revis shown exhibit believ consensu fulli
updat preliminari result
compani file factset secur llc estim
compani file secur llc estim
jacob hugh senior analyst fargo secur million ex per share fiscal year end decemb statementconsum sc sc chg expens expens incom per specialti pharmaceut
price target nc
price target base dcf valuat includ discount rate termin
multipl dcf factor liabil tax disput risk includ integr turnaround
brand consum healthcar busi rx pharmaceut valuat spin and/or sale tax
disput irish tax author
sidelin stock sale trend improv turnaround
look invest year earn approx flat lsd growth potenti larg
call cash irish tax disput
began packag gener home remedi year later one top
over-the-count over-the-counter consum good product compani market share privat label
store brand also among lead compani pharmaceut gener market
well activ pharmaceut ingredi api market
